The week in pharma: action, reaction and insight - week to November 12, 2021

tpl-week-in-review-700x466

By Barbara Obstoj-Cardwell

Significant news last week including UK Pharma major GlaxoSmithKline releasing positive new data on its daprodustat as a new option for anemia in kidney disease. Deal-making developments featured Pfizer entering an agreement that could cost it up to $1.2 billion to gain certain rights to Biohaven Pharma’s migraine drug Nurtec. Also, Roche subsidiary Genentech inked a license and research collaboration with US start-up Novome Biotechnologies on inflammatory bowel disease (IBD). Meantime, Japan’s Kyowa Kirin gained a positive recommendation for its rare blood cancer drug Poteligeo from the UK’ health technology assessor the NICE. Additionally, health care giant Johnson & Johnson surprised markets, with the announcement that it is splitting out its Consumer Health business into a separate publicly-traded company.

GlaxoSmithKline’s daprodustat delivers

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical